|Dr. Jean-Paul Kress||CEO & Management Board Member||2.03M||N/A||1965|
|Mr. Jens H. Holstein||CFO & Member of the Management Board||1.43M||N/A||1964|
|Dr. Malte Peters||Chief Devel. Officer & Member of the Management Board||1.37M||N/A||1962|
|Mr. Klaus De Wall||Head of Accounting & Tax||N/A||N/A||N/A|
|Ms. Lara Smith Weber||Head of Controlling, Corp. Fin. & Corp. Devel.||N/A||N/A||N/A|
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys' investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.
MorphoSys AG’s ISS governance QualityScore as of 3 December 2019 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 1; Compensation: 5.